Does this patient need treatment for a minor unilateral frontal-temporal hair recession?

Treatment is Recommended Even for Minor Unilateral Frontal-Temporal Hair Recession

Yes, this patient should be treated, because frontal fibrosing alopecia (FFA) causes permanent, irreversible hair loss, and early intervention is critical to prevent progression—even when recession appears minor or asymmetric. The natural history of FFA is unpredictable: some patients stabilize spontaneously while others experience relentless progression over years 1, 2. Since you cannot predict which trajectory an individual patient will follow, and because follicular destruction is permanent, the window for intervention closes rapidly.

Why Treat Minor or Unilateral Disease?

• Hair loss is irreversible: FFA is a scarring alopecia with inflammatory destruction of hair follicles 1. Once follicles are destroyed, they cannot regenerate.

• Unpredictable progression: One patient's hairline receded 30mm over 72 months, while another showed no change after 15 years 1. You cannot reliably predict who will progress rapidly.

• Asymmetric presentation is recognized: While bilateral frontotemporal recession is typical, asymmetric frontal involvement has been documented 2, so unilateral presentation doesn't exclude the diagnosis or reduce treatment urgency.

• Early treatment may modify disease course: Although evidence is limited by lack of placebo-controlled trials, early intervention is encouraged in active disease because treatment could potentially alter the natural history 3.

Recommended Treatment Algorithm

Based on the most recent Spanish consensus from 2026 4, which represents the highest-quality guideline evidence available:

Initiate multimodal therapy immediately with complementary mechanisms:

1. Oral dutasteride (5α-reductase inhibitor) as the foundation

   • Most commonly used therapy with 88% positive response rate (158/180 patients) 3
   • In a multicenter study of 355 patients, antiandrogens (finasteride/dutasteride) showed improvement in 47% and stabilization in 53% 5

2. Plus topical and/or intralesional corticosteroids

   • Intralesional triamcinolone acetonide showed 88% positive response (181/204 patients) 3
   • Addresses the inflammatory component directly at affected sites

3. Add hydroxychloroquine if inflammation persists 4

   • Second-line systemic anti-inflammatory agent

4. Consider low-dose oral minoxidil (LDOM) for cosmetic improvement

   • A 2026 prospective study showed LDOM 1mg/day improved anterior hairline coverage in 9/10 women with FFA 6
   • This enhances coverage of remaining hairs but doesn't stop the scarring process
   • Monitor blood pressure and pulse, especially 2 hours after dosing 7
   • Watch for dose-related side effects: hypertrichosis (typically temples/sideburns in first 3 months), fluid retention (2-4 months), dizziness 7

Critical Pitfalls to Avoid

• Don't wait to see if it progresses: The "wait and see" approach risks permanent, irreversible hair loss during observation.

• Don't rely on oral prednisone: It only temporarily delays rapid hair loss and is seldom used 3.

• Don't assume unilateral = less aggressive: Asymmetric patterns are documented, and severity markers include eyelash loss, facial papules, and body hair involvement—not laterality 5.

• Don't use monotherapy: The 2026 consensus emphasizes multimodal therapy with complementary mechanisms because hair loss is irreversible 4.

Monitoring for Disease Activity

Look for signs of active inflammation that warrant aggressive treatment:

• Perifollicular erythema at the hairline
• Follicular hyperkeratosis
• Progressive recession on serial photography
• Associated eyebrow loss (73% of patients) 2
• Facial papules or body hair involvement (markers of severe disease) 5

The combination of irreversible follicular destruction, unpredictable natural history, and evidence supporting early intervention makes treatment imperative—even for seemingly minor unilateral recession.